Research Article

Cytokine profiling of exosomes derived from the plasma of HIV-infected alcohol drinkers and cigarette smokers

Sunitha Kodidela¹, Sabina Ranjit¹, Namita Sinha¹, Carole McArthur², Anil Kumar³, Santosh Kumar¹*¹

¹ Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN, United States of America, ² Department of Oral and Craniofacial Science, School of Dentistry, University of Missouri-Kansas City, Kansas City, Missouri, United States of America, ³ Division of Pharmacology and Toxicology, School of Pharmacy, University of Missouri-Kansas City, Kansas City, Missouri, United States of America

* ksantosh@uthsc.edu.

Abstract

Cytokines and chemokines circulate in plasma and may be transferred to distant sites, via exosomes. HIV infection is associated with dysregulation of cytokines and chemokines, which subsequently contribute to the pathogenesis of HIV. Alcohol and tobacco exposure, which are prevalent in HIV-infected individuals, may induce changes in the expression of cytokines and chemokines. Therefore, our aim in this study was to quantify plasma exosomal cytokines and chemokines that we expect to exacerbate toxicity or disease progression in HIV-positive drug abusers. We measured the levels of cytokines and chemokines in the plasma and plasma exosomes of 39 patients comprising six groups: HIV-negative and HIV-positive non drug abusers, HIV-negative and HIV-positive alcohol users, and HIV-negative and HIV positive tobacco smokers. We measured six cytokines (TNF-α, IL-1β, IL-8, IL-6, IL-1ra, IL-10) and two chemokines (MCP-1 and RANTES). All were present in exosomes of healthy subjects, but their levels varied between different study groups. HIV-positive alcohol drinkers had higher levels of plasma IL-8 compared to those of HIV-positive non-drinkers. The IL-1ra level was significantly higher in exosomes of non-HIV-infected alcohol drinkers compared to those of HIV-positive alcohol drinkers. Interestingly, the IL-10 level was higher in exosomes compared with their respective plasma levels in all study groups except HIV-positive non-drinkers. The IL-1ra level was significantly higher in exosomes of non-HIV-infected alcohol drinkers compared to those of HIV-positive alcohol drinkers. Interestingly, the IL-10 level was higher in exosomes compared with their respective plasma levels in all study groups except HIV-positive non-drinkers. IL-10 was completely packaged in exosomes of HIV-positive smokers. HIV-positive smokers had significantly higher levels of plasma IL-8 compared with HIV-positive non-smokers and significantly higher exosomal IL-6 levels compared with HIV-negative subjects. HIV-positive smokers had significantly increased plasma levels of IL-1ra compared to HIV-positive non-smokers. The MCP-1 levels in the plasma of HIV-positive smokers was significantly higher than in either HIV-positive non-drug abusers or HIV-negative smokers. Overall, the findings suggest that plasma cytokines and chemokines are packaged in exosomes at varying degrees in different study groups. Exosomal cytokines and chemokines are likely to have a significant biological role at distant sites including cells in the brain.
Introduction

Abuse of alcohol and tobacco is prevalent among HIV-infected individuals. In the USA, the percentage of alcohol and tobacco use among HIV-infected individuals are 40% [1] and 42% [2], respectively. Systematic reviews on studies conducted among Africans strongly suggest an association between alcohol use and HIV infection in those populations [3–5]. Alcohol increases the risk of infection and also exacerbates HIV replication [6–9]. Moreover, alcohol reduces adherence to antiretroviral therapy (ART) and decreases ART efficacy, which could further increase HIV replication [10–12]. Similarly, smoking increases HIV replication by multiple mechanisms [13,14]. In vivo and in vitro studies demonstrate that tobacco smoking is associated with decreased immune response [15,16], increased inflammation [17] and oxidative stress [18–21], and increased occurrence of opportunistic infections [22,23]. In addition, pharmacokinetic interactions between smoking and ART drugs decrease the efficacy of ART, which could lead to progression of AIDS [24].

HIV infection is associated with chronic immune activation [25,26] and dysregulation of cytokines and chemokines, which subsequently contribute to the pathogenesis of HIV. Interactions between immune cells occur by direct cell-cell contact or through cytokine secretion. These cytokines are also likely to be circulated in plasma and transferred to other distant cells via exosomes. Exosomes, small extracellular vesicles (<200 nm), have recently been recognized as extremely valuable targets for biological research [27,28]. Their semi-selective ability to package and transport diverse biological cargos such as proteins, mRNAs, micro RNAs, and small molecules allow them to serve both as diagnostic biomarkers of disease states [29–32], and as potential therapeutic targets [29,33]. Konadu et al. have shown that the exosomes of HIV-seropositive patients have higher cytokine levels than those of HIV-seronegative individuals [30]. The expression of these cytokines may vary in the case of alcohol or tobacco exposure since the plasma cytokine levels of HIV-positive drug abusers are significantly different from HIV-positive non-abusers. However, cytokine levels in the plasma-derived exosomes of HIV-positive alcohol and tobacco abusers have not been studied. Moreover, studying the cytokine levels in exosomes is important, because the exosomal contents are more stable than freely circulating molecules and can have long-lasting effects [34]. A recent study from our lab has shown that exosomes derived from macrophages alter cytotoxicity and HIV replication when exposed to naive macrophages [35]. As the HIV-induced immunomodulation might be altered by substance abuse (e.g. alcohol and tobacco), there is a need to identify a physiological marker to indicate the immune status of HIV patients with drug abuse disorders. We hypothesize that alcohol and tobacco use alter the expression of specific cytokines in exosomes in the plasma of HIV patients, that may be associated with enhanced toxicity and disease progression in HIV-positive drug abusers.

Materials and methods

Study design and subjects

We conducted a cross-sectional study consisting of 39 subjects after approval of the Institutional Review Board from the University of Missouri-Kansas City, in Kansas City, MO and the Institutional Ethics Committee from the Provincial Regional Hospital of the Ministry of Public Health in Bamenda, Cameroon. Written informed consent was obtained from all study participants and their medical history was collected during the recruitment. The study subjects belong to six different groups: HIV-negative non-drug abusers, (n = 10), HIV-positive non-drug abusers (n = 5), HIV-negative alcohol drinkers (n = 6), HIV-positive alcohol drinkers (n = 3), HIV-negative tobacco smokers (n = 11), and HIV-positive tobacco users (n = 4).
Subjects were recruited as described in our earlier studies [9,14]. Briefly, patients between the ages of 20–65 years were recruited. The inclusion criteria for tobacco smokers were for those who smoke at least one pack of cigarettes per day for ≤ 20 years (mild-to-moderate tobacco users), and, for alcohol drinkers, those who drink 7–14 drinks/week for men and 4–7 drinks/week for women for the previous 6 months (mild-to-moderate alcohol users). The CD4 count (cells/μl) of HIV-positive non-drug abusers, HIV-positive tobacco users, and HIV-positive alcohol users ranged between 256–551, 412–584, and 321–480, respectively. The exclusion criteria of our study population were as described previously [9,14].

**Exosome isolation and characterization**

We isolated exosomes from plasma using an exosome precipitation kit (Invitrogen). Briefly, plasma exosomes from study subjects were isolated by filtering plasma through a 0.22 μm filter to remove large vesicles (>200 nm) followed by precipitation using the exosome isolation kit (Invitrogen). Fifty μl of plasma from each subject was centrifuged at 2,000 g for 20 min followed by at 10,000 g for 20 min to remove any cell debris. The supernatant was transferred to a new tube and 0.5 volumes of PBS was added to it, followed by addition of 0.2 volumes of exosome precipitation reagent. The reaction mixture was incubated at room temperature for 10 min. After incubation, the sample was centrifuged at 10,000 g for 5 min, which resulted in the pure exosome pellet. We then characterized the size and zeta potential of exosomes by dynamic light scattering using a Zetasizer Nano-ZS (Malvern Instruments Inc, Malvern, UK) as described (31,35). We also characterized the exosomes for expression of the exosomal marker proteins CD63, CD81, and/or Alix by Western blotting. The size, shape, and quality of exosomes was characterized by transmission electron microscopy with a JEOL 2000EXII (The Neuroscience Institute, University of Tennessee Health Science Center) as described previously [31,35]. We also quantified exosomes by measuring acetylcholinesterase (AchE) activity using a validated Amplex® Red Acetylcholine/Acetylcholinesterase Assay Kit (Molecular Probes, Invitrogen). Briefly, the exosome pellet was suspended in 100 μl of 50 mM Tris-HCl (pH 8.0) and incubated with 100 μL of the Amplex Red reagent containing 2 U/mL HRP, 0.2 U/mL choline oxidase, and 100 μM acetylcholine in a final volume of 200 μl. An aliquot of 100 μl (0.2 U/mL) acetylcholinesterase solution was used as positive control, and 100 μl 10 μM H2O2 working solution was used as second positive control. The reaction plate was incubated for more than 1 hour at room temperature in the dark. Fluorescence was measured every 15 min at λ_ex and λ_em of 530 nm and 590 nm, respectively. The optimal activity of AchE was observed at 45 min. The concentration of AchE in exosomes was between the ranges of 0.2–0.4 U/L/μg.

**Cytokine measurement**

The protein levels of various cytokines and chemokines such as pro-inflammatory: TNF-α, IL-1β, IL-8, IL-6; anti-inflammatory: IL-1ra, IL-10; and chemokines: MCP-1, and RANTES in plasma and exosomes were measured using validated human Bio-Plex Pro Assays (Bio-RAD, CA, USA). Exosomes and plasma samples were diluted with Bio-Plex sample diluent and samples were prepared for the cytokine analysis according to the manufacturer’s instructions. The concentration (pg/ml) of eight different cytokines and chemokines were measured using a Luminex 200™ system, and the data were analyzed using xPONENT® software (S1 Dataset).

**Statistical analysis**

The concentrations of cytokines and chemokines were presented as median and inter-quartile range. The Mann–Whitney U test was used to compare between plasma samples and their
respective exosomes, as well as, among plasma and exosomes of different groups. The data were analyzed using Graph-Pad Prism version 5.00 (GraphPad Software, La Jolla, CA, USA). A P-value of \( \leq 0.05 \) was considered statistically significant.

Results

Comparison of plasma and exosomal cytokines and chemokines between HIV-negative non-drug abusers, HIV-positive, HIV-negative drinkers, and HIV-positive drinker subjects

**Pro-inflammatory cytokines.** In general, the plasma pro-inflammatory cytokine levels in all the groups were higher than their respective exosomal cytokine levels (Fig 1 and Table 1). The relative percentages of plasma TNF-\( \alpha \), IL-1\( \beta \), IL-8, and IL-6 packaged in exosomes of

![Fig 1. Box and whisker plots of pro-inflammatory cytokines between HIV-negative non-drug abusers (healthy), HIV-positive non-drug abusers (HIV), HIV-negative alcohol drinkers (alcohol), and HIV-positive alcohol drinker (HIV+alcohol) subjects. The box represents the 25\(^{th}\)-75\(^{th}\) quartile, the whiskers represent the range of values, the median is presented as a line inside the box, and the out-of-range values are presented as circles. Mann–Whitney U test was used to compare between the plasma and their respective exosomes of different study groups, and significant p-values are represented as \#(p \leq 0.05) and ##(p \leq 0.01). Comparison of cytokine levels among plasma as well as exosomes of different groups were done using Mann–Whitney U test, and significant p-values are given as * (p \leq 0.05), ** (p \leq 0.01) and $ (p \leq 0.05), $ (p \leq 0.01), respectively.](https://doi.org/10.1371/journal.pone.0201144.g001)
healthy subjects were 6%, 15%, 18%, and 0.66% respectively. TNF-α, IL-1β, and IL-8 were lower in HIV-positive subjects than HIV-negative subjects and similar to those obtained in alcohol drinkers. Although the level of IL-1β was higher in plasma samples of most groups than their respective exosomes, it was absent in plasma, but detectable in exosomes, of HIV subjects. IL-8 was not detectable in the exosomes of HIV patients. There was a significant difference in IL-8 levels between the plasma samples of HIV-negative and HIV-infected subjects. Further, IL-8 level were higher in plasma samples of HIV-positive drinkers than HIV-positive non-alcohol drinkers. The IL-6 was non-detectable in plasma samples of all the study groups except the HIV-positive group (Fig 1 and Table 1). Moreover, IL-6 was packaged in exosomes of HIV-negative subjects only, and was absent in other studied groups.

### Anti-inflammatory cytokines

The percentage of plasma IL-1ra packaged in exosomes of HIV-negative subjects was relatively high at 39%. The IL-1ra level was detectable in both the plasma and exosomes of all of the studied groups, and, as expected, the level was relatively lower in exosomes than the respective plasma samples. The IL-1ra level was significantly

### Table 1. Comparison of cytokine and chemokine levels between HIV-negative and positive alcohol users.

| Cytokine   | HIV-negative non-drug abusers (N = 10) | HIV-positive (N = 5) | p-value | HIV-negative alcohol users (N = 6) | p-value | HIV-positive drinkers (N = 3) | p-value |
|------------|----------------------------------------|----------------------|---------|----------------------------------|---------|-----------------------------|---------|
| **Pro-inflammatory** |                                      |                      |         |                                  |         |                            |         |
| TNF-α      | Plasma 20 (7.4–32)                      | 4.8*                 | NA      | 7.4 (4.3–9.3)                    | 0.08    | 11 (6.1–16)                 | 0.35    |
|            | Exosome 0.8 (0.7–2)                     | 1.5 (0.5–4)         | 0.77    | 0.79 (0.51–4.0)                  | 0.80    | 1.7 (1.2–2.2)               | 0.66    |
|            | p-value 0.001                           | 0.02                | NA      |                                  | 0.10    |                            |         |
| IL-1β      | Plasma 0.97 (0.31–2.2)                  | ND                   | NA      | 0.26 (0.19–2.4)                  | 0.58    | 0.75 (0.26–1.3)             | 0.65    |
|            | Exosome 0.20 (0.06–0.31)                | 0.06*               | NA      | 0.36 (0.36–0.36)                 | NA      | NA                          | NA      |
|            | p-value 0.07                            | NA                   | NA      |                                  |         |                            |         |
| IL-8       | Plasma 7.0 (5.6–11)                     | 1.3 (0.64–2.0)       | 0.002   | 5.8 (3.8–8.9)                    | 0.35    | 4.9 (3.80–6.90)             | 0.14    |
|            | Exosome 1.5 (0.94–3.0)                  | ND                   | NA      | 4.7 (0.94–8.5)                   | 0.36    | 0.95 (0.40–1.46)            | 0.35    |
|            | p-value 0.0007                          | 0.76                 | NA      |                                  | NA      |                            | NA      |
| IL-6       | Plasma 2.6 (1.4–3.7)                    | ND                   | NA      | ND                               | NA      | ND                          | NA      |
|            | Exosome 0.67 (0.12–1.2)                 | ND                   | NA      | ND                               | NA      | NA                          | NA      |
|            | p-value NA                              | NA                   | NA      |                                  | NA      |                            | NA      |
| **Anti-inflammatory** |                                  |                      |         |                                  |         |                            |         |
| IL-1ra     | Plasma 93.0 (36.2–128)                  | 41 (35–73)          | 0.42    | 139 (105–193)                    | 0.08    | 90 (65–98)                  | 0.93    |
|            | Exosome 42 (9.4–49)                     | 9.4 (3.0–9.4)       | 0.06    | 23 (15–53)                       | 0.88    | 9.4 (3.4–12)                | 0.10    |
|            | p-value 0.10                            | 0.03                 | 0.008   |                                  | 0.10    |                            |         |
| IL-10      | Plasma 1.1 (0.61–1.7)                   | 0.61 (0.11–3.3)     | 0.82    | ND                               | NA      | ND                          | NA      |
|            | Exosome 1.4 (0.75–1.9)                  | ND                   | NA      | 0.59 (0.06–3.3)                  | 0.60    | 1.1 (0.83–1.4)              | 0.60    |
|            | p-value 0.53                            | NA                   | NA      |                                  | NA      |                            | NA      |
| **Chemokines** |                                |                      |         |                                  |         |                            |         |
| RANTES     | Plasma 7052 (2852–15233)                | 13365 (8947–15416)  | 0.37    | 6973 (821.4–10500)               | 0.56    | 7262 (4843–25638)           | 0.69    |
|            | Exosome 530.8 (320.2–1744)              | 232 (149–871)       | 0.37    | 698.6 (327.7–2509)               | 0.71    | 706.8 (593.5–4118)          | 0.28    |
|            | p-value 0.001                           | 0.007                | 0.09    |                                  | 0.10    |                            |         |
| MCP-1      | Plasma 31.4 (19.3–87.2)                 | 139 (5.0–23)        | 0.02    | 36 (25–69)                       | 0.58    | 35 (24–99)                  | 0.57    |
|            | Exosome 3.8 (1.5–4.7)                   | 0.74*               | NA      | 3.2 (2.4–13)                     | 0.56    | 5.8 (3.4–6.9)               | 0.21    |
|            | p-value 0.0001                          | NA                   | 0.02    |                                  | 0.10    |                            |         |

Values are expressed as median (25th-75th inter-quartile range); a-detectable only in one sample, b-Comparison between HIV-positive non-alcohol drinkers and HIV-positive alcohol groups, c-Comparison between HIV-negative alcohol drinkers and HIV-positive alcohol drinkers, ND-not detectable; NA-not applicable

https://doi.org/10.1371/journal.pone.0201144.t001
higher in exosomes of HIV-negative alcohol users compared to those of HIV-positive drinkers, and to some extent compared to HIV-positive non-drinkers. Interestingly, the IL-10 level was high in exosomes compared to their respective plasma samples of all study groups except HIV-positive non-drinkers. Further, IL-10 was completely packaged in exosomes of alcohol drinkers and HIV-positive drinkers, and was not detected in their plasma samples. (Fig 2 and Table 1).

Chemokines. Relative to plasma, 12% of RANTES and 7% of MCP-1 were packaged in exosomes in uninfected non-drug abusers. Similar to cytokines (Figs 1 and 2), in general, the chemokine levels in exosomes were lower than those of respective plasma samples (Fig 3). More specifically, RANTES level was significantly higher in plasma than exosomes of healthy and HIV-positive subjects, while MCP-1 level was higher in plasma than exosomes of HIV-negative non-drug abusers and HIV-negative alcohol drinkers. Though not statistically significant, there is a pattern of relatively increased median levels of RANTES, but decreased median levels of MCP-1 in HIV subjects, compared with other groups.

Comparison of plasma and exosomal cytokine and chemokine levels between HIV-negative non-drug abusers, HIV-positive, HIV-negative smokers, and HIV-positive smoker subjects

Pro-inflammatory cytokines. Similar to the HIV-negative and HIV-positive non-drug abusers, the levels of all the pro-inflammatory cytokines were relatively lower in exosomes than their respective plasma samples of HIV-positive and -negative smokers, especially TNF-α in HIV-positive smokers, which was undetectable in exosomes. HIV-positive smokers also had significantly higher levels of plasma IL-8 than HIV-positive non-smokers (Fig 4, Table 2). Interestingly, IL-6 was packaged in exosomes of all the study groups except the HIV-positive...
non-drug abusers, even though IL-6 was not detectable in the plasma of the healthy, smoker,
and HIV-positive smoker groups. The HIV-positive smokers had significantly higher exoso-
mal IL-6 levels than those of HIV-negative subjects (Fig 4, Table 2).

**Anti-inflammatory cytokines.** Similar to pro-inflammatory cytokines (Fig 2), the level of
IL-1ra in exosomes was relatively lower than the respective plasma samples of smokers and
HIV-positive smokers (Fig 5). However, IL-10 exhibited different characteristics than the
other cytokines in terms of its relative level in exosomes compared to plasma. The median IL-
1ra level in plasma was relatively higher in HIV-positive smokers than in healthy and smoker
subjects, and significantly higher than HIV subjects. Interestingly, the level of IL-10 in exo-
somes was similar to that of plasma in healthy and smoker subjects, and it was completely
packaged in exosomes of HIV-positive smokers (Fig 5, Table 2)

**Chemokines.** Similarly to the results presented in Fig 3, the chemokines RANTES and
MCP-1 showed significantly higher levels in plasma than exosomes obtained from smokers
and HIV-positive smokers. Importantly, the MCP-1 level in plasma of HIV-positive smokers
was significantly higher than the HIV and smoker groups (Fig 6, Table 2). Eosomes of HIV-
positive smokers had significantly higher levels of RANTES than those of smoker or healthy
subjects. Exosomal MCP-1 also showed a relatively increased level in HIV-positive smokers
compared to both HIV and smoker subjects.

**Discussion**

We conducted a cross-sectional study to determine the expression of cytokines and chemok-
ines in the exosomes of HIV-infected individuals and/or drug abusers. We also studied the
relative packaging of cytokines and chemokines into exosomes of HIV-positive and/or drug-
abusing subjects. As the HIV-induced immunomodulation might be altered by alcohol and
tobacco abuse, there is a need to identify a physiological marker to indicate the immune status of HIV patients with drug abuse disorders. The present study could potentially provide an important biomarker for HIV patients with altered immune function due to drug abuse. In this study, we observed that some cytokines can be selectively packaged in exosomes, and their levels vary depending on the conditions of their exposure. This is the first study on the analysis of the relative levels of plasma exosomal cytokines and chemokines in HIV-positive drug abusers.

HIV infection is associated with increased expression of pro-inflammatory cytokines and chemokines [36,37]. In the present study, the cytokine/chemokine levels were relatively low in plasma samples from the HIV group relative to the healthy group, except for IL-6 and RANTES. Pro-inflammatory cytokines have been reported to be high in HIV-positive African women without an AIDS diagnosis, compared to those with AIDS [38], suggesting that pro-
inflammatory cytokines could be involved only in the early phase of infection. Thus, the unaltered or decreased pro-inflammatory cytokines in our study population may indicate the stage of HIV progression to AIDS. Further, our samples were recruited from a region of Africa where access to ART is limited, [39] which could have led to the enrollment of subjects with an advanced stage of HIV infection. Our findings are concordant with Mack M et al study which reported high levels of IL-6 in HIV-infected patients [40].

Among the studied cytokines and chemokines, TNF-α (40%), MCP-1(5%), IL-1ra (14%), and RANTES (3%) were packaged into exosomes, in HIV-infected non-drug abusers. Literature reports suggest that exosomes facilitate HIV replication by mechanisms such as transfer of viral entry receptors (CCR5 and CXCR4) [41,42], miRNA [43,44], and viral proteins (Nef) [45,46]. However, the study of the role of exosomal cytokines in HIV replication is in its infancy. Exosomes can transport cytokine-inducing molecules such as HIV TAR RNA [47].

### Table 2. Comparison of cytokine and chemokine levels between HIV-negative subjects, HIV-positive non-drug abusers, HIV-negative smokers, and HIV-positive non-smokers.

| Cytokine | HIV-negative non-drug abusers (N = 10) | HIV-positive non-drug abusers (N = 5) | p-value | HIV-negative Smoker (N = 11) | p-value | HIV-positive smoker (N = 4) | p-value | p-value |
|----------|----------------------------------------|---------------------------------------|---------|------------------------------|---------|----------------------------|---------|---------|
| **Pro-inflammatory** | | | | | | | | |
| TNF-α | Plasma 20 (7.4–32) | 4.8* | NA | 12 (6.3–46) | 0.99 | 14 (8.0–35) | 0.99 | NA 0.91 |
| Exosome 0.81 (0.69–2.5) | 0.77 | 1.1 (0.81–3.3) | 0.41 | ND | NA | NA | NA |
| p-value 0.001 | NA | 0.01 | NA | | | | | |
| IL-1β | Plasma 0.97 (0.31–2.2) | ND | NA | 1.7 (0.25–3.2) | 0.90 | 2.72 (1.2–4.1) | 0.13 | ND 0.58 |
| Exosome 0.20 (0.06–0.31) | 0.064* | NA | 0.78 (0.37–1.0) | 0.07 | 0.080* | NA | NA | NA |
| p-value | | | | | | | | |
| IL-8 | Plasma 7.1 (5.6–11) | 1.3 (0.64–2.0) | 0.002 | 3.7 (1.7–7.9) | 0.06 | 10 (4.0–22) | 0.72 | 0.01 0.21 |
| Exosome 1.5 (0.95–3.0) | ND | NA | 1.5 (0.69–1.8) | 0.74 | 3.3 (1.5–4.2) | 0.29 | NA 0.16 |
| p-value 0.0007 | NA | 0.02 | NA | | | | | |
| IL-6 | Plasma ND | 2.6 (1.4–3.7) | NA | ND | NA | ND | NA |
| Exosome 0.67 (0.12–1.2) | ND | NA | 6.8 (1.3–21) | 0.19 | 2.5 (0.35–4.7) | 0.0001 | NA 0.38 |
| p-value | NA | NA | NA | | | | | |
| **Anti-inflammatory** | | | | | | | | |
| IL-1ra | Plasma 93.0 (36.1–128) | 41 (35–73) | 0.42 | 38.6 (23.7–193) | 0.45 | 156 (82.3–231) | 0.18 | 0.03 0.17 |
| Exosome 42.2 (9.4–50) | 9.4 (3.0–9.4) | 0.05 | 16 (6.3–31) | 0.09 | 31 (12–42) | 0.64 | 0.07 0.35 |
| p-value 0.10 | 0.03 | 0.03 | 0.05 | | | | | |
| IL-10 | Plasma 1.1 (0.61–1.7) | 0.61 (0.11–3.3) | 0.82 | 1.7 (0.11–2.1) | 0.82 | ND | NA | NA |
| Exosome 1.4 (0.75–1.9) | ND | NA | 0.62 (0.47–1.7) | 0.28 | 1.2 (0.90–1.5) | 0.77 | NA 0.47 |
| p-value 0.53 | NA | 0.90 | NA | | | | | |
| **Chemokines** | | | | | | | | |
| RANTES | Plasma 7052 (2852–15233) | 13365 (8947–15416) | 0.37 | 5239 (2256–10194) | 0.69 | 19997 (1152–46594) | 0.63 | 0.99 0.94 |
| Exosome 530.8 (320.2–1744) | 232 (149–871) | 0.37 | 197.5 (121.7–1059) | 0.16 | 1875 (1026–2781) | 0.14 | 0.06 0.04 |
| p-value 0.001 | 0.007 | 0.0016 | 0.68 | | | | | |
| MCP-1 | Plasma 31 (19–87) | 13. (5.01–23) | 0.02 | 20 (18–38) | 0.34 | 62.8 (36.3–126) | 0.37 | 0.01 0.02 |
| Exosome 3. 8 (1.5–4.7) | 0.74* | NA | 4.0 (1.6–6.4) | 0.72 | 3.56 (2.1–19) | 0.99 | NA 0.79 |
| p-value 0.0001 | NA | 0.0008 | NA | | | | | |

Values are expressed as median (25th-75th inter-quartile range)

* - detectable only in one sample

b - Comparison between HIV-positive non-tobacco smokers and HIV-positive tobacco smokers

c - Comparison between HIV-negative tobacco smokers and HIV-positive tobacco smokers, ND - not detectable; NA - not applicable

https://doi.org/10.1371/journal.pone.0201144.t002
Fig 5. Box and whisker plots of anti-inflammatory cytokines between HIV-negative non-drug abusers (healthy), HIV-positive non-drug abusers (HIV), HIV-negative smokers (smokers) and HIV-positive smoker (HIV+smoker). For comparison with other study groups, the bar graphs for healthy and HIV subjects were replicated from Fig 2. The box represents the 25th-75th quartile, the whiskers represent the range of values, the median is presented as a line inside the box, and the out-of-range values are presented as circles. The Mann–Whitney U test was used to compare between plasma and exosomes of different study groups as well as and significant p-values are represented as # (p<0.05) and ## (p<0.01). Comparison of cytokine levels among plasma as well as exosomes of different groups were done using the Mann–Whitney U test and significant p-values are given as * (p<0.05), ** (p<0.01) and $ (p<0.05), $$ (p<0.01), respectively.

https://doi.org/10.1371/journal.pone.0201144.g005

Fig 6. Box and whisker plots of chemokines between HIV-negative non-drug abusers (healthy), HIV-positive non-drug abusers (HIV), HIV-negative smokers (smokers) and HIV-positive smoker (HIV+smoker). For comparison with other study groups, the bar graphs for healthy and HIV subjects were replicated from Fig 3. The box represents the 25th-75th quartile, the whiskers represent the range of values, the median is presented as a line inside the box, and the out-of-range values are presented as circles. The Mann–Whitney U test was used to compare between plasma and exosomes of different study groups as well as and significant p-values are represented as # (p<0.05) and ## (p<0.01). Comparison of cytokine levels among plasma as well as exosomes of different groups were done using the Mann–Whitney U test and significant p-values are given as * (p<0.05), ** (p<0.01) and $ (p<0.05), $$ (p<0.01), respectively.

https://doi.org/10.1371/journal.pone.0201144.g006
and Nef protein [48] from HIV-infected cells, thereby increasing cytokine expression in recipient cells. Apart from cytokine-inducing molecules, exosomes are also reported to carry cytokines themselves [30,49], which may exacerbate HIV replication. Our findings are consistent with studies by Konadu et al. and Johnson et al., who showed that plasma exosomes of HIV-infected individuals carry cytokines [30,49]. Konadu et al. also reported that exosomes derived from HIV-seropositive patients had significantly higher levels of cytokines than the exosomes of HIV-seronegative patients [30]. However, in our study, there was no difference in exosomal cytokine levels between healthy and HIV groups, except IL6 and perhaps RANTES, which could be due in part to small sample size. Furthermore, the array of cytokines, that we have tested for is different from that considered by other studies.

Alcohol exposure regulates the production and function of signaling molecules that coordinate the immune response in alcoholic liver disease and influence the cross-talk between liver parenchymal and immune cells [50]. Interactions between immune cells can occur by direct cell-cell contact and/or by cytokine production. These cytokines can be transferred to distant cells via secretion into the plasma, or by exosomal transport. In the present study, IL-10 was not detectable in plasma samples but was found in the plasma exosomes of alcohol users. The percentages of the cytokines TNF-α, MCP-1, IL-8, IL-1ra, and RANTES packaged in exosomes, compared to plasma, were 28%, 18%, 75%, 14%, and 25%, respectively, indicating a potentially significant role of exosomes in mediating the effects of these cytokines on recipient cells. We have previously demonstrated that plasma derived exosomes provoke an inflammatory response in recipient mice in vivo [51]. Elevated levels of the pro-inflammatory cytokines TNF-α, IL-1β, and IL-8 have been observed in alcoholic liver disease patients [52]. Further, ethanol induces extracellular vesicle production and incubation of these vesicles with naïve monocytes results in the production of cytokines by the recipient cells [53]. IL-10 plays a role in reducing alcoholic liver injury and inflammation [54,55]. In the present study, complete packaging of IL-10 in exosomes derived from alcohol-drinking subjects may indicate the role of exosomes in mediating the protective effects of IL-10 against alcohol-induced liver injury. Our results support a finding where EVs derived from alcohol-exposed monocytes have been reported to stimulate IL-10 production in naïve monocytes [53]. Therefore, investigating the protective role of exosomal IL-10 in alcohol-exposed cells may provide insights in using exosomes as a therapeutic agent to reduce alcohol-induced liver injury. Further, exosomes can serve as biomarker of alcohol-induced liver injury as the exosome numbers were strongly correlated with a marker of liver injury, AST levels (r = 0.80), in the presence of alcohol [56]. Apart from carrying cytokines, hepatocyte-derived exosomes also carry cytokine-inducing agents to macrophages in the event of alcohol exposure, indicating the cross talk between hepatic exosomes and immune cells [57]. Therefore, exosomes may play an important role in alcohol-induced tissue damage by altering cytokine production.

Alcohol consumption increases susceptibility to HIV infection by affecting the nutrition and immunological functions of a person [58]. Further, acute or chronic alcohol consumption has been reported to increase HIV replication [59,60] and dysregulate cytokine production [61,62], it is also associated with poor adherence to ART therapy [63,64]. Alcohol abuse also causes neuro-inflammation [65,66] and increases the risk of secondary infections [67], thereby decreasing survival rates in HIV patients [68]. In our study, we investigated cytokine levels in exosomes of HIV-positive alcohol drinkers to find a potential marker to diagnose alcohol-induced toxicity in HIV patients. HIV-positive alcohol drinkers had significantly lower levels of exosomal IL-1ra compared to HIV-negative alcohol drinkers (p = 0.02; Table 1), and there was no change in levels when compared with the HIV-positive non-drinkers (Table 1). Similar to the alcohol group, IL-10 was completely packaged in exosomes of HIV-positive drinkers. Moreover, compared to plasma, the percentage of the cytokines TNF-α, IL-8, MCP-1,
RANTES and IL-1ra, packaged in exosomes of HIV positive alcohol users are 15%, 10%, 14%, 14%, and 10% respectively. The cytokines packaged in exosomes are more stable than the circulating biological molecules [34] and can cross the blood-brain barrier [69,70]. Studying exosomal cytokines may reveal optimistic views towards diagnosis and therapeutic treatments for alcohol-induced toxicity in HIV patients.

All the studied cytokines were present in the plasma as well as the exosomes of smokers, except for IL-6, which was completely packaged in exosomes. Though not statistically significant, both plasma and exosomes from smokers had higher levels of IL-1β compared to those of healthy subjects. Cigarette smoking is associated with variations in production of inflammatory markers [71]. For example, increased levels of IL-1β and IL-1ra have been observed in bronchoalveolar lavage of smokers, whereas their levels were decreased in cancer patients who smoke [71]. Tobacco smoking status has been shown to affect plasma cytokine levels in different phenotypes of chronic obstructive pulmonary disease [72]. Therefore, cytokine expression varies based on the smoking status of an individual, which perhaps could have been contributed to differences in the outcome of studies. We have also studied the cytokine levels in the exosomes of smokers and found that IL-6 is completely packaged in exosomes. Further, relative to plasma, 11% of TNF-α, 42% of IL-1β, 18% of IL-8, 19% of MCP-1, 19% of IL-1ra, and 11% of RANTES were packaged in exosomes. Very few studies have been conducted on the role of exosomal cytokine levels in smoking-induced inflammation. Alveolar macrophages have been reported to release exosomes upon stimulation and these exosomes were shown to carry the protein suppressor of cytokine signaling 1 (SOCS1). Incubation of alveolar epithelial cells with exosomes derived from alveolar macrophages showed the uptake of exosomes containing SOCS1 protein and inhibit cytokine-induced signaling in these cells [73]. Further, the release of SOCS1-containing vesicles was significantly reduced in smokers compared with non-smokers [73], which suggests that impaired activity of SOCS1 may contribute to the inflammatory responses that are associated with tobacco smoke exposure. Moreover, the expression of IL-6 and TNF-α were negatively correlated with the expression of SOCS1 in macrophages upon cigarette smoke exposure [74]. These findings suggests that exosomes can be used as a mediators to target cytokine signaling pathways in case of smoking-induced inflammation.

Smoking is also known to exacerbate HIV replication by various mechanisms. Cytokine levels were found to be altered in HIV-positive smokers compared to HIV negative smokers [14]. Smoking induces cytokine production, which is involved in HIV infection [75,76]. Interestingly, in our study, HIV-positive smokers had significantly higher levels of plasma IL-8, MCP-1, and IL-1ra compared to HIV-positive non-smokers. In addition, HIV-positive smokers had significantly higher levels of plasma MCP-1 compared to those of HIV-negative smokers. Exosomes of HIV-positive smokers contained IL-1β (3%), IL-8 (24%), MCP-1 (11%), IL-1ra (18%), and RANTES (8%). Interestingly, IL-6 and IL-10 were not detectable in exosomes of HIV patients but were present in exosomes of both HIV-positive and uninfected smokers. HIV-positive smokers had higher exosomal IL-6 than healthy subjects, and higher exosomal RANTES than HIV-negative smokers. RANTES causes resistance to HIV infection by downregulating the CCR5 receptor, a chemokine receptor and co-receptor for viral entry, there by blocking HIV [77–79]. Complete packaging of IL-10, an anti-inflammatory cytokine, and increased RANTES levels in HIV-positive smokers may indicate that smoking induces cytokines in exosomes, which reduce HIV replication. Recently, a study from our group has shown that exosomes derived from macrophages exposed to tobacco constituents protect against cytotoxicity and reduce HIV replication in macrophages [35]. Further investigation of the roles of exosomal contents derived from murine models of HIV and drug abuse may provide potential data on the in vivo role of these exosomal cytokines.
Conclusion and future directions

The present findings suggest that plasma cytokines are packaged in exosomes. Increased cytokine levels in plasma as well as exosomes of HIV-positive drug abusers, when compared with HIV and drug abuse groups alone, suggest a novel mechanism of pathogenesis in cases of drug abuse and HIV comorbidity. Despite a relatively low number of subjects, the current study provides an evidence of the role of specific plasma exosomal cytokines and chemokines, which are specifically packaged in HIV-infected drug abusers compared with only HIV or drug abuse groups. This finding also provides important information on packaging of specific cytokines and chemokines under HIV and drugs of abuse conditions, which is an important step towards finding potential biomarkers for the interaction between HIV and drugs of abuse. We are in the process of recruiting large cohorts from these groups in the USA, which would provide further information about the role of plasma exosomal cytokines and chemokines in the interaction between HIV and drugs of abuse. We do expect that plasma exosomal cytokine levels would vary between mild-to-moderate and heavy drug abusers, and studying the relative exosomal cytokine levels in subjects with different degrees of drug abuse would provide valuable information about how it can affect the systemic immune response, and thus could be a promising avenue for future investigation.

Supporting information

S1 Dataset. Cytokine and chemokine levels in plasma and exosomes of HIV-negative non-drug abusers (Healthy), HIV-positive non-drug abusers (HIV), HIV-negative alcohol drinkers (alcohol), HIV-positive alcohol drinkers (HIV+alcohol), HIV-negative smokers (smoker), and HIV-positive smokers (HIV+smokers).

Acknowledgments

We gratefully acknowledge the faculty and staff at the Molecular Research Center at UTHSC for the use of their Bioplex machine.

We thank Benjamin J Patters at the College of Pharmacy, UTHSC, for critically review of the manuscript.

Author Contributions

Conceptualization: Sunitha Kodidela, Santosh Kumar.

Formal analysis: Sunitha Kodidela.

Funding acquisition: Santosh Kumar.

Investigation: Sunitha Kodidela, Sabina Ranjit, Namita Sinha, Carole McArthur, Anil Kumar, Santosh Kumar.

Writing – original draft: Sunitha Kodidela.

Writing – review & editing: Sabina Ranjit, Carole McArthur, Anil Kumar, Santosh Kumar.

References

1. Chander G, Josephs J, Fleishman JA, Korthuis PT, Gaist P, Hellinger J, et al. Alcohol use among HIV-infected persons in care: results of a multi-site survey. HIV Med. 2008; 9: 196–202. https://doi.org/10.1111/j.1468-1293.2008.00545.x PMID: 18366443
2. Mdodo R, Frazier EL, Dube SR, Mattson CL, Sutton MY, Brooks JT, et al. Cigarette smoking prevalence among adults with HIV compared with the general adult population in the United States: cross-sectional surveys. Ann Intern Med. 2015; 162: 335–344. https://doi.org/10.7326/M14-0954 PMID: 25732274

3. Kalichman SC, Simbayi LC, Kaufman M, Cain D, Jooste S. Alcohol use and sexual risks for HIV/AIDS in sub-Saharan Africa: systematic review of empirical findings. Prev Sci Off J Soc Prev Res. 2007; 8: 141–151. https://doi.org/10.1007/s11121-006-0061-2 PMID: 17265194

4. Cook RL, Clark DB. Is there an association between alcohol consumption and sexually transmitted diseases? A systematic review. Sex Transm Dis. 2005; 32: 156–164. PMID: 15729152

5. Fisher JC, Banh H, Kapiga SH. The association between HIV infection and alcohol use: a systematic review and meta-analysis of African studies. Sex Transm Dis. 2007; 34: 856–863. https://doi.org/10.1097/OLQ.0b013e318067bf4d PMID: 18049422

6. May 15 CSCHB last updated; 2017. Alcohol and Drug Use and HIV Risk. In: HIV.gov [Internet]. 15 May 2017 [cited 16 Mar 2018]. Available: https://www.hiv.gov/hiv-basics/hiv-prevention/reducing-risk-from-alcohol-and-drug-use/alcohol-and-drug-use-and-hiv-risk

7. Bagby GJ, Stolitz DA, Zhang P, Kolls JK, Brown J, Bohm RP, et al. The effect of chronic binge ethanol consumption on the primary stage of SIV infection in rhesus macaques. Alcohol Clin Exp Res. 2003; 27: 495–502. https://doi.org/10.1097/01.ALC.000007947.57330.BE PMID: 12658116

8. Hahn JA, Woolf-King SE, Muyindike W. Adding fuel to the fire: alcohol’s effect on the HIV epidemic in Sub-Saharan Africa. Curr HIV/AIDS Rep. 2011; 8: 172–180. https://doi.org/10.1007/s11904-011-0088-2 PMID: 21713433

9. Ande A, Sinha N, Rao PSS, McArthur CP, Ayuk L, Achu PN, et al. Enhanced oxidative stress by alcohol use in HIV+ patients: possible involvement of cytochrome P450 2E1 and antioxidant enzymes. AIDS Res Ther. 2015; 12. https://doi.org/10.1186/s12981-015-0071-x PMID: 26396584

10. Parsons JT, Rosof E, Mustanski B. The temporal relationship between alcohol consumption and HIV-medication adherence: a multilevel model of direct and moderating effects. Health Psychol Off J Div Health Psychol Am Psychol Assoc. 2008; 27: 628–637. https://doi.org/10.1037/a0012664 PMID: 18831899

11. García de Olalla P, Knobel H, Carmona A, Guelar A, López-Colomés JL, Caylá JA. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr 1999. 2002; 30: 105–110.

12. Kumar S, Jin M, Ande A, Sinha N, Silverstein PS, Kumar A. Alcohol consumption effect on antiretroviral therapy and HIV-1 pathogenesis: role of cytochrome P450 isozymes. Expert Opin Drug Metab Toxicol. 2012; 8: 1363–1375. https://doi.org/10.1517/17425255.2012.714366 PMID: 22871069

13. Marshall MM, McCormack MC, Kirk GD. Effect of Cigarette Smoking on HIV Acquisition, Progression, and Mortality. AIDS Educ Prev Off Publ Int Soc AIDS Educ. 2009; 21: 28–39. https://doi.org/10.1521/aepa.2009.21.3_supp.28 PMID: 19537952

14. Ande A, McArthur C, Ayuk L, Awasom C, Achu PN, Njinda A, et al. Effect of Mild-to-Moderate Smoking on Viral Load, Cytokines, Oxidative Stress, and Cytochrome P450 Enzymes in HIV-Infected Individuals. PLOS ONE. 2015; 10: e0122402. https://doi.org/10.1371/journal.pone.0122402 PMID: 25879453

15. Mehta H, Nazza K, Sadikot RT. Cigarette smoking and innate immunity. Inflamm Res Off J Eur Histamine Res Soc Al. 2008; 57: 497–503. https://doi.org/10.1007/s00011-008-0087-6 PMID: 19109742

16. Singh SP, Kalra R, Puttfarken P, Kozak A, Tesfaigzi J, Sopori ML. Acute and chronic nicotine exposures modulate the immune system through different pathways. Toxicol Appl Pharmacol. 2000; 164: 65–72. https://doi.org/10.1006.taap.2000.8897 PMID: 10739745

17. Hodge-Bell KC, Lee KM, Renne RA, Gideon KM, Harbo SJ, McKinney WJ. Pulmonary inflammation in mice exposed to mainstream cigarette smoke. Inhal Toxicol. 2007; 19: 361–376. https://doi.org/10.1080/08958730701144076 PMID: 17365041

18. van der Vaart H, Postma DS, Timens W, ten Hacken NHT. Acute effects of cigarette smoke on inflammation and oxidative stress: a review. Thorax. 2004; 59: 713–721. https://doi.org/10.1136/thx.2003.012486 PMID: 15282359

19. Arimilli S, Schmidt E, Damratski BE, Prasadi GL. Role of Oxidative Stress in the Suppression of Immune Responses in Peripheral Blood Mononuclear Cells Exposed to Combustible Tobacco Product Preparation. Inflammation. 2017; 40: 1622–1630. https://doi.org/10.1007/s10753-017-0602-9 PMID: 28577134

20. Jin M, Earla R, Shah A, Earla RL, Gupte R, Mitra AK, et al. A LC-MS/MS method for concurrent determination of nicotine metabolites and role of CYP2A6 in nicotine metabolism in U937 macrophages: implications in oxidative stress in HIV+ smokers. J Neuroimmune Pharmacol Off J Soc NeuroImmune Pharmacol. 2012; 7: 289–299. https://doi.org/10.1007/s11481-011-9283-6 PMID: 21655912
21. Earla R, Ande A, McArthur C, Kumar A, Kumar S. Enhanced Nicotine Metabolism in HIV-1-positive Smokers Compared to HIV-negative Smokers: Simultaneous Determination of Nicotine and its Four Metabolites in their Plasma Using a Simple and Sensitive ESI-LC-MS/MS Technique. Drug Metab Dispos. 2013; 113:055186. https://doi.org/10.1124/dmd.113.055186 PMID: 24301609

22. McMaster SK, Paul-Clark MJ, Walters M, Fleet M, Anandarajah J, Sriskandan S, et al. Cigarette smoke inhibits macrophage sensing of Gram-negative bacteria and lipopolysaccharide: relative roles of nicotine and oxidant stress. Br J Pharmacol. 2008; 153: 536–543. https://doi.org/10.1038/bsjp.0707595 PMID: 18059323

23. Miguez-Burbano MJ, Burbano X, Ashkin D, Plichtenik A, Allan R, Pineda L, et al. Impact of tobacco use on the development of opportunistic respiratory infections in HIV seropositive patients on antiretroviral therapy. Addict Biol. 2003; 8: 39–43. https://doi.org/10.1080/10865250210129927 PMID: 12745414

24. Kumar S, Rao PSS, Earla R, Kumar A. Drug-drug interactions between antiretroviral therapies and drugs of abuse in HIV systems. Expert Opin Drug Metab Toxicol. 2015; 11: 343–355. https://doi.org/10.1517/17425255.2015.996546 PMID: 25539046

25. Klatt NR, Chomont N, Douek DC, Deeks SG. Immune activation and HIV persistence: implications for curative approaches to HIV infection. Immunol Rev. 2013; 254: 326–342. https://doi.org/10.1111/imr.12065 PMID: 23772629

26. Sereti I, Altfeld M. Immune activation and HIV: an enduring relationship. Curr Opin HIV AIDS. 2016; 11: 129–130. https://doi.org/10.1097/COH.0000000000000244 PMID: 26845672

27. Samanta S, Rajasingh S, Drosos N, Zhou Z, Dawn B, Rajasingh J. Exosomes: new molecular targets of diseases. Acta Pharmacol Sin. 2017; https://doi.org/10.1038/aps.2017.162 PMID: 29219950

28. Wu K, Xing F, Wu S-Y, Watabe K. Extracellular vesicles as emerging targets in cancer: Recent development from bench to bedside. Biochim Biophys Acta. 2017; 1868: 538–563. https://doi.org/10.1016/j.bbcan.2017.10.001 PMID: 29054476

29. Lin J, Li J, Huang B, Liu J, Chen X, Chen X-M, et al. Exosomes: novel biomarkers for clinical diagnosis. ScientificWorldJournal. 2015; 2015: 657086. https://doi.org/10.1155/2015/657086 PMID: 25695100

30. Konadu KA, Chu J, Huang MB, Amancha PK, Armstrong W, Powell MD, et al. Association of Cytokines With Exosomes in the Plasma of HIV-1-Seropositive Individuals. J Infect Dis. 2015; 211: 1712–1716. https://doi.org/10.1093/infdis/jiu867 PMID: 25512626

31. Kumar S, Sinha N, Gerth KA, Rahaman MA, Yaliapu MM, Midde NM. Specific packaging and circulation of cytochromes P450, especially 2E1 isozyme, in human plasma exosomes and their implications in cellular communications. Biochim Biophys Res Commun. 2017; 491: 675–680. https://doi.org/10.1016/j.bbrc.2017.07.145 PMID: 28756226

32. Kumar S. Plasma Exosomes and Drug Metabolic Cytochrome P450 Enzymes. J Drug Metab Toxicol. 2015; 6. https://doi.org/10.4172/2157-7609.1000e124

33. Sarko DK, McKinney CE. Exosomes: Origins and Therapeutic Potential for Neurodegenerative Disease. Front Neurosci. 2017; 11: 82. https://doi.org/10.3389/fnins.2017.00082 PMID: 28289371

34. Sarker S, Scholz-Romoero K, Perez A, Illanes SE, Mitchell MD, Rice GE, et al. Placenta-derived exosomes continuously increase in maternal circulation over the first trimester of pregnancy. J Transl Med. 2014; 12. https://doi.org/10.1186/1475-5766-12-204 PMID: 25104112

35. Haque S, Sinha N, Ranjit S, Midde NM, Kashanchi F, Kumar S. Monocyte-derived exosomes upon exposure to cigarette smoke condensate alter their characteristics and show protective effects against cytotoxicity and HIV-1 replication. Sci Rep. 2017; 7: 16120. https://doi.org/10.1038/s41598-017-16301-9 PMID: 29170477

36. Kedzierska K, Crowe SM. Cytokines and HIV-1: interactions and clinical implications. Antivir Chem Chemother. 2001; 12: 133–150. https://doi.org/10.1077/0956-3202.101200301 PMID: 12995322

37. Emilie D, Fior R, Jarrousse B, Marfaing-Koka A, Merrien D, Devergne O, et al. Cytokines in HIV infection. Int J Immunopharmacol. 1994; 16: 391–396. PMID: 7927984

38. Thea DM, Korat R, Nagimbi K, Baangi M, St Louis ME, Kaplan G, et al. Plasma cytokines, cytokine antagonists, and disease progression in African women infected with HIV-1. Ann Intern Med. 1996; 124: 757–762. PMID: 8633837

39. 2016_04_hiv_report_eng.pdf [Internet]. Available: https://www.msf.org/sites/msf.org/files/2016_04_hiv_report_eng.pdf

40. Breen EC, Rezai AR, Nakajima K, Beall GN, Mitsuyasu RT, Hirano T, et al. Infection with HIV is associated with elevated IL-6 levels and production. J Immunol Baltim Md 1950. 1990; 144: 480–484.

41. Mack M, Kleinschmidt A, Brühl H, Klier C, Nelson P.J, Cihak J, et al. Transfer of the chemokine receptor CCR5 between cells by membrane-derived microparticles: a mechanism for cellular human immunodeficiency virus 1 infection. Nat Med. 2000; 6: 769–775. https://doi.org/10.1038/77498 PMID: 10888925
42. Rozmyslowicz T, Majka M, Kijowski J, Murphy SL, Conover DO, Poncz M, et al. Platelet- and megakaryocyte-derived microparticles transfer CXCR4 receptor to CXCR4-null cells and make them susceptible to infection by X4-HIV. AIDS Lond Engl. 2003; 17: 33–42. https://doi.org/10.1097/01.aids.0000042948.95433.3d PMID: 12478067

43. Wang X, Ye L, Hou W, Zhou Y, Wang Y-J, Metzger DS, et al. Cellular microRNA expression correlates with susceptibility of monocytes/macrophages to HIV-1 infection. Blood. 2009; 113: 671–674. https://doi.org/10.1182/blood-2008-09-175000 PMID: 19015395

44. Chevillet JR, Kang Q, Ruf IK, Briggs HA, Vojtech LN, Hughes SM, et al. Quantitative and stoichiometric analysis of the microRNA content of exosomes. Proc Natl Acad Sci U S A. 2014; 111: 14888–14893. https://doi.org/10.1073/pnas.1408301111 PMID: 25267620

45. Teow S-Y, Nordin AC, Ali SA, Khoo AS-B. Exosomes in Human Immunodeficiency Virus Type I Pathogenesis: Threat or Opportunity? Adv Virol. 2016; 2016: 9852494. https://doi.org/10.1155/2016/9852494 PMID: 26981123

46. Madison MN, Okeoma CM. Exosomes: Implications in HIV-1 Pathogenesis. Viruses. 2015; 7: 4093–4118. https://doi.org/10.3390/v7072810 PMID: 26205405

47. Sampey GC, Saifuddin M, Schwab A, Barclay R, Punya S, Chung M-C, et al. Exosomes from HIV-1-infected Cells Stimulate Production of Pro-inflammatory Cytokines through Trans-activating Response (TAR) RNA. J Biol Chem. 2016; 291: 1251–1266. https://doi.org/10.1074/jbc.M115.662171 PMID: 26553869

48. Lenassi M, Cagney G, Liao M, Vaupotic T, Bartholomeeusen K, Cheng Y, et al. HIV Nef is secreted in exosomes and triggers apoptosis in bystander CD4+ T cells. Traffic Cph Den. 2010; 11: 110–122. https://doi.org/10.1111/j.1600-0854.2009.01006.x PMID: 19912576

49. Johnson K, Chi J, Huang M, Powell M, Villinger F, Bond V. Innate cytokines associate with exosomes in plasma of HIV-1+ individuals (P6205). J Immunol. 2013; 190: 118.26–118.26.

50. Cohen JL, Nagy LE. Pathogenesis of alcoholic liver disease: interactions between parenchymal and non-parenchymal cells. J Dig Dis. 2011; 12: 3–9. https://doi.org/10.1111/j.1751-2980.2010.00468.x PMID: 21091930

51. Li JJ, Wang B, Kodali MC, Chen C, Kim E, Patters BJ, et al. In vivo evidence for the contribution of peripheral circulating inflammatory exosomes to neuroinflammation. J Neuroinflammation. 2018; 15: 8. https://doi.org/10.1186/s12974-017-0388-6 PMID: 29310666

52. McClain CJ, Barve S, Decau i C, Kugelmass M, Hill D. Cytokines in alcoholic liver disease. Semin Liver Dis. 1999; 19: 205–219. https://doi.org/10.1055/s-2007-1007110 PMID: 10422201

53. Saha B, Momen-Heravi F, Kodys K, Szabo G. MicroRNA Cargo of Extracellular Vesicles from Alcohol-exposed Monocytes Signals Naive Monocytes to Differentiate into M2 Macrophages. J Biol Chem. 2016; 291: 149–159. https://doi.org/10.1074/jbc.M115.694133 PMID: 26527689

54. Kawaratai H, Tsujimoto T, Douhara A, Takaya H, Moriya K, Namisaki T, et al. The effect of inflammatory cytokines in alcoholic liver disease. Mediators Inflamm. 2013; 2013: 495156. https://doi.org/10.1155/2013/495156 PMID: 24385684

55. Louis H, Le Moine O, Goldman M, Devière J. Modulation of liver injury by interleukin-10. Acta Gastro-Enterol Belg. 2003; 66: 7–14.

56. Momen-Heravi F, Saha B, Kodys K, Catalano D, Satishchandran A, Szabo G. Increased number of circulating exosomes and their microRNA cargos are potential novel biomarkers in alcoholic hepatitis. J Transl Med. 2015; 13: 261. https://doi.org/10.1186/s12967-015-0623-9 PMID: 26264599

57. Momen-Heravi F, Bala S, Kodys K, Szabo G. Exosomes derived from alcohol-treated hepatocytes horizontally transfer liver specific miRNA-122 and sensitize monocytes to LPS. Sci Rep. 2015; 5: 9991. https://doi.org/10.1038/srep09991 PMID: 25973575

58. Bagasra O, Kajdacsy-Balla A, Lischner HW. Effects of alcohol ingestion on in vitro susceptibility of peripheral blood mononuclear cells to infection with HIV and of selected T-cell functions. Alcohol Clin Exp Res. 1989; 13: 636–643. PMID: 2574543

59. Bagasra O, Bachman SE, Jew L, Tawadros R, Cater J, Boden G, et al. Increased human immunodeficiency virus type 1 replication in human peripheral blood mononuclear cells induced by ethanol: potential immunopathogenic mechanisms. J Infect Dis. 1996; 173: 550–558. PMID: 8627016

60. Bagasra O, Kajdacsy-Balla A, Lischner HW, Pomerantz RJ. Alcohol intake increases human immunodeficiency virus type 1 replication in human peripheral blood mononuclear cells. J Infect Dis. 1993; 167: 789–797. PMID: 8450242

61. Wang JY, Liang B, Watson RR. Alcohol consumption alters cytokine release during murine AIDS. Alcohol Fayettev N. 1997; 14: 155–159.
62. Wang Y, Watson RR. Chronic ethanol consumption before retrovirus infection is a cofactor in the development of immune dysfunction during murine AIDS. Alcohol Clin Exp Res. 1994; 18: 976–981. PMID: 7978112

63. Kekwaletswe CT, Morojele NK. Patterns and predictors of antiretroviral therapy use among alcohol drinkers at HIV clinics in Tshwane, South Africa. AIDS Care. 2014; 26 Suppl 1: S78–82. https://doi.org/10.1080/09540121.2014.906558 PMID: 24731102

64. Morojele NK, Kekwaletswé CT, Nkosi S. Associations between alcohol use, other psychosocial factors, structural factors and antiretroviral therapy (ART) adherence among South African ART recipients. AIDS Behav. 2014; 18: 519–524. https://doi.org/10.1007/s10461-013-0583-0 PMID: 23934270

65. Potula R, Haorah J, Knipe B, Leibhart J, Chrastil J, Heilman D, et al. Alcohol abuse enhances neuroinflammation and impairs immune responses in an animal model of human immunodeficiency virus-1 encephalitis. Am J Pathol. 2006; 168: 1335–1344. https://doi.org/10.2353/ajpath.2006.051181 PMID: 16565506

66. Persidsky Y, Ho W, Ramirez SH, Potula R, Abood ME, Unterwald E, et al. HIV-1 infection and alcohol abuse: neurocognitive impairment, mechanisms of neurodegeneration and therapeutic interventions. Brain Behav Immun. 2011; 25 Suppl 1: S61–70. https://doi.org/10.1016/j.bbi.2011.03.001 PMID: 21397004

67. Silverstein PS, Kumar S, Kumar A. HIV-1, HCV and Alcohol in the CNS: Potential Interactions and Effects on Neuroinflammation. Curr HIV Res. 2014; 12: 282–292. PMID: 25053363

68. Fuster D, Cheng DM, Quinn EK, Armor KA, Saltz R, Freiberg MS, et al. Inflammatory cytokines and mortality in a cohort of HIV-infected adults with alcohol problems. AIDS Lond Engl. 2014; 28: 1059–1064. https://doi.org/10.1097/QAD.0000000000000184 PMID: 24401638

69. Chen CC, Liu L, Ma F, Wong CW, Guo XE, Chacko JV, et al. Elucidation of Exosome Migration across the Blood-Brain Barrier Model In Vitro. Cell Mol Bioeng. 2016; 9: 509–529. https://doi.org/10.1007/s12195-016-0458-3 PMID: 28392840

70. Wood MJ, O’Loughlin AJ, Lakhal S. Exosomes and the blood–brain barrier: implications for neurological diseases. Ther Deliv. 2011; 2: 1095–1099. https://doi.org/10.4155/tde.11.83 PMID: 22833906

71. Shiels MS, Katki HA, Freedman ND, Purdue MP, Wentzensen N, Trabert B, et al. Cigarette smoking and variations in systemic immune and inflammation markers. J Natl Cancer Inst. 2014; 106. https://doi.org/10.1093/jnci/dju294 PMID: 25274579

72. Nakamura M, Nakamura H, Minematsu N, Chubachi S, Miyazaki M, Yoshida S, et al. Plasma cytokine profiles related to smoking-sensitivity and phenotypes of chronic obstructive pulmonary disease. Biomark Biochem Indic Expo Respons Chem. 2014; 19: 368–377. https://doi.org/10.3109/1354750X.2014.915342 PMID: 24842387

73. Bourdonnay E, Zaslona Z, Penke LRK, Speth JM, Schneider DJ, Przybranowski S, et al. Transcellular delivery of vesicular SOCS proteins from macrophages to epithelial cells blunts inflammatory signaling. J Exp Med. 2015; 212: 729–742. https://doi.org/10.1084/jem.20141675 PMID: 25847945

74. Dong R, Xie L, Zhao K, Zhang Q, Zhou M, He P. Cigarette smoke-induced lung inflammation in COPD mediated via LTB4/BLT1/SOCS1 pathway. Int J Chron Obstruct Pulmon Dis. 2016; 11: 31–41. https://doi.org/10.2147/COPD.S96412 PMID: 26730186

75. Iho S, Tanaka Y, Takao K, Zhang Q, Zhou M, He P. Nicotine induces human neutrophils to produce IL-8 through the generation of peroxynitrite and subsequent activation of NF-kappaB. J Leukoc Biol. 2003; 74: 942–951. https://doi.org/10.1189/jlb.1202626 PMID: 12960242

76. Le Saout C, Lane HC, Catalafamo M. The Role of Cytokines in the Pathogenesis and Treatment of HIV Infection. Cytokine Growth Factor Rev. 2012; 23: 207–214. https://doi.org/10.1016/j.cytogfr.2012.05.007 PMID: 22738931

77. Arenzana-Seisdedos F, Parmentier M. Genetics of resistance to HIV infection: Role of co-receptors and co-receptor ligands. Semin Immunol. 2006; 18: 387–403. https://doi.org/10.1016/j.smim.2006.07.007 PMID: 16978874

78. Coccia F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science. 1995; 270: 1811–1815. PMID: 8525373

79. Promadhat-Lanier N, Hanson DL, Srinivaasan P, Luo W, Adams DR, Guenthner PC, et al. Resistance to SIVmac HIV infection is associated with high plasma interleukin-8, RANTES and Eotaxin in a macaque model of repeated virus challenges. J Acquir Immune Defic Syndr. 1999. 2010; 53: 574–581. https://doi.org/10.1097/QAI.0b013e3181d352f1 PMID: 20164782